ABSTRACT
Herpes simplex encephalitis (HSE) is an acute form of encephalitis that can lead to poor neurological outcomes. Although the exact pathogenesis of HSE remains elusive, recent reports suggest a significant role for postinfectious immune-inflammatory processes in the central nervous system (CNS). This study aimed to clarify the association between CNS autoimmune responses and clinical presentation in patients with HSE, focusing on cerebrospinal fluid (CSF) characteristics, particularly the IgG index. We retrospectively analyzed 176 consecutive patients suspected of having aseptic meningitis /encephalitis for chronological changes in CSF findings and clinical presentations. These patients underwent PCR screening for herpesviruses (HV) in their CSF. We identified seven patients positive for herpes simplex virus type 1 (HSV-1), 20 patients positive for varicella-zoster virus, and 17 patients who met the criteria for aseptic meningitis but were PCR-negative for HV. Patients in the HSV-1-positive group exhibited a significant increase in the IgG index at the time of PCR-negative conversion compared with on admission (p = 0.0156), while such a change was not observed in the other two groups. Additionally, all patients in the HSV-1-positive group tested negative for anti-neural autoantibodies in CSF and serum samples collected approximately 3 weeks after onset. This study, therefore, highlights that CSF IgG index elevation occurs even after PCR-confirmed HSV-1 clearance, which might indicate immunopathogenesis that is independent of antibody-mediated mechanisms.
Subject(s)
Antibodies, Viral , Encephalitis, Herpes Simplex , Herpesvirus 1, Human , Immunoglobulin G , Humans , Immunoglobulin G/cerebrospinal fluid , Immunoglobulin G/blood , Female , Male , Encephalitis, Herpes Simplex/cerebrospinal fluid , Encephalitis, Herpes Simplex/immunology , Herpesvirus 1, Human/immunology , Retrospective Studies , Middle Aged , Adult , Aged , Antibodies, Viral/cerebrospinal fluid , Antibodies, Viral/blood , Young Adult , Adolescent , Herpesvirus 3, Human/immunology , Polymerase Chain Reaction , Autoantibodies/cerebrospinal fluid , Autoantibodies/blood , Aged, 80 and over , Child , Cerebrospinal Fluid/virology , Cerebrospinal Fluid/immunologyABSTRACT
Enterovirus (EV) infections have various symptoms and severe complications, including death. To determine EV prevalence and EV types in Slovenia, data on over 25 000 EV RNA tests for diagnostics and surveillance from 2014 to 2023 were analyzed. Altogether, 3733 cerebrospinal fluid (CSF) and 21 297 respiratory (sentinel and clinical) samples were tested for EV RNA. EV typing was performed on all residual EV-positive CSF samples and on subset of respiratory specimens. Altogether, 1238 samples tested positive for EV RNA: 238 (6.4%) CSF and 1000 (4.7%) respiratory samples. EV-positive patients were predominantly male (p < 0.001). Many EV-positive CSF samples were from infants under 3 months (33.1%), whereas most EV-positive respiratory samples were from children 1 to 2 years old (49.2%). Echovirus 30 (E-30) was most frequent in CSF (33.0%), followed by CV-B5 (13.8%) and E-6 (13.8%). CV-A6 was most frequent in respiratory samples (16.0%), followed by EV-D68 (7.6%) and CV-A5 (7.4%). EV types in CSF and respiratory samples show diverse dynamics, with some outbreaks indicated. A significant difference was found in the EV detection rate between CSF and respiratory samples by age. Various EV types were characterized, showing that some EV types are more neurotropic or cause more severe infections.
Subject(s)
Enterovirus Infections , Enterovirus , Molecular Epidemiology , Humans , Slovenia/epidemiology , Infant , Male , Enterovirus Infections/epidemiology , Enterovirus Infections/virology , Enterovirus Infections/cerebrospinal fluid , Female , Child, Preschool , Enterovirus/genetics , Enterovirus/isolation & purification , Enterovirus/classification , Child , Adolescent , RNA, Viral/genetics , RNA, Viral/cerebrospinal fluid , Respiratory Tract Infections/virology , Respiratory Tract Infections/epidemiology , Respiratory Tract Infections/cerebrospinal fluid , Infant, Newborn , Adult , Young Adult , Prevalence , Cerebrospinal Fluid/virology , Genotype , Middle Aged , Aged , PhylogenyABSTRACT
Accurate detection and quantification of cytomegalovirus (CMV) is crucial to preventing adverse outcomes in immunocompromised individuals. Current assays were developed for use with plasma specimens, but CMV may be present in bronchoalveolar lavage (BAL) fluid and cerebrospinal fluid (CSF). We evaluated the performance of the Abbott Alinity m CMV assay compared to the Abbott RealTime CMV assay for quantification of CMV in plasma, BAL, and CSF specimens. To evaluate clinical performance, 190 plasma, 78 BAL, and 20 CSF specimens were tested with the Alinity m assay and compared to the RealTime assay. The Alinity m CMV assay showed high precision (SD <0.01 to 0.13) for all 3 specimen types. Clincal plasma and BAL specimens with quantifiable CMV DNA demonstrated strong correlation to RealTime CMV assay results (r2 = 0.9779 for plasma, r2 = 0.9373 for BAL). The Alinity m CMV assay may be useful for quantification of CMV in plasma, BAL, and CSF specimens.
Subject(s)
Bronchoalveolar Lavage Fluid , Cerebrospinal Fluid , Cytomegalovirus Infections , Cytomegalovirus , Humans , Bronchoalveolar Lavage Fluid/virology , Cytomegalovirus Infections/diagnosis , Cytomegalovirus Infections/cerebrospinal fluid , Cytomegalovirus Infections/virology , Cytomegalovirus/isolation & purification , Cytomegalovirus/genetics , Cerebrospinal Fluid/virology , Molecular Diagnostic Techniques/methods , Molecular Diagnostic Techniques/standards , Sensitivity and Specificity , Viral Load , Plasma/virology , DNA, Viral/cerebrospinal fluidABSTRACT
Cryptococcus neoformans is the most common cause of fungal meningitis and is associated with a high mortality. The clinical significance of concurrent Epstein-Barr virus (EBV) in the cerebrospinal fluid (CSF) of human immunodeficiency virus (HIV)-negative patients with cryptococcal meningitis (CM) remains unclear. A retrospective cohort study was performed by analyzing CSF samples from 79 HIV-negative Chinese Han patients with confirmed CM. We identified CSF viral DNA in these patients by metagenomic next-generation sequencing (mNGS) and compared 10-week survival rates among those with and without EBV DNA in CSF. Of the 79 CSF samples tested, 44.3% (35/79) had detectable viral DNA in CSF, while 55.7% (44/79) were virus-negative. The most frequent viral pathogen was EBV, which was detected in 22.8% (18/79) patients. The median number of CSF-EBV DNA reads was 4 reads with a range from 1 to 149 reads. The 10-week mortality rates were 22.2% (4/18) in those with positive CSF-EBV and 2.3% (1/44) in those with negative CSF-virus (hazard ratio 8.20, 95% confidence interval [CI] 1.52-81.80; P = 0.014), which remained significant after a multivariate adjustment for the known risk factors of mortality (adjusted hazard ratio 8.15, 95% CI 1.14-92.87; P = 0.037). mNGS can identify viruses that coexist in CSF of HIV-negative patients with CM. EBV DNA is most commonly found together with C. neoformans in CSF and its presence is associated with increased mortality in HIV-negative CM patients.
We retrospectively analyzed CSF samples from 79 HIV-negative Chinese Han patients with confirmed CM. We identified CSF viral DNA by mNGS and compared 10-week survival rates among those with and without EBV DNA. Positive CSF-EBV DNA is associated with the increased mortality in HIV-negative CM patients.
Subject(s)
DNA, Viral , Epstein-Barr Virus Infections , Herpesvirus 4, Human , Meningitis, Cryptococcal , Humans , Meningitis, Cryptococcal/mortality , Meningitis, Cryptococcal/cerebrospinal fluid , Meningitis, Cryptococcal/microbiology , Male , Female , Retrospective Studies , Adult , Middle Aged , Herpesvirus 4, Human/genetics , Herpesvirus 4, Human/isolation & purification , DNA, Viral/cerebrospinal fluid , DNA, Viral/genetics , Epstein-Barr Virus Infections/complications , Epstein-Barr Virus Infections/mortality , Epstein-Barr Virus Infections/cerebrospinal fluid , Aged , Cerebrospinal Fluid/microbiology , Cerebrospinal Fluid/virology , Cryptococcus neoformans/genetics , Cryptococcus neoformans/isolation & purification , High-Throughput Nucleotide Sequencing , Metagenomics , Young Adult , China/epidemiology , Survival AnalysisABSTRACT
OBJECTIVE: Central nervous system (CNS) HIV infection can impact cognition and may be an obstacle to cure in adolescents and young adults with perinatal HIV (AYAPHIV). IMPAACT2015 enrolled AYAPHIV on suppressive antiretroviral therapy (ART) with cognitive impairment to detect and quantify HIV in blood and cerebrospinal fluid (CSF). DESIGN: IMPAACT2015 was a U.S.-based multi-site, exploratory, observational study. METHODS: Cognitive impairment was defined as NIH Toolbox Fluid Cognition Composite score (FCCS) more than 1 standard deviation below age-adjusted normative group mean. Cell-free HIV-RNA and cell-associated HIV pol/gag -DNA and 10 biomarkers of inflammation/neuronal injury were measured in paired CSF and blood. ART exposure concentrations were quantified in hair. RESULTS: Among 24 participants, 20 had successful CSF collection and 18 also met viral suppression criteria. Nine of 18 (50%) were female sex-at-birth, and 14 of 18 (78%) were black. Median (range) age was 20âyears (13-27), time on ART was 18.3âyears (8.0-25.5), and FCCS was 68 (53-80). HIV-DNA was detected in PBMCs from all participants. In CSF, two of 18 (11%, 95% CI: 1.4-34.7%) participants had detectable cell-free HIV-RNA, while HIV gag or pol -DNA was detectable in 13 of 18 (72%, 95% confidence interval: 47-90). Detectable HIV-DNA in CSF was associated with male sex-at-birth ( P â=â0.051), lower CD4 + cell count at enrollment ( P â=â0.016), and higher PBMC HIV pol -DNA copies ( P â=â0.058). Hair antiretroviral concentrations and biomarkers were not associated with CSF HIV-DNA detection. CONCLUSION: We found that a high proportion of AYAPHIV with neurocognitive impairment had CSF cells harboring HIV-DNA during long-term virologic suppression. This evidence of persistent HIV-DNA in CSF suggests that the CNS should be considered in treatment and cure studies.
Subject(s)
Anti-Retroviral Agents , DNA, Viral , HIV Infections , RNA, Viral , Humans , Female , Male , HIV Infections/drug therapy , HIV Infections/complications , Adolescent , DNA, Viral/cerebrospinal fluid , Young Adult , Adult , RNA, Viral/cerebrospinal fluid , Anti-Retroviral Agents/therapeutic use , Prevalence , Cognitive Dysfunction , United States/epidemiology , Cerebrospinal Fluid/virology , Biomarkers/cerebrospinal fluidABSTRACT
PURPOSE: Investigation of undiagnosed cases of infectious neurological diseases, especially in the paediatric population, remains a challenge. This study aimed to enhance understanding of viruses in CSF from children with clinically diagnosed meningitis and/or encephalitis (M/ME) of unknown aetiology using shotgun sequencing enhanced by hybrid capture (HCSS). METHODS: A single-centre prospective study was conducted at Sant Joan de Déu University Hospital, Barcelona, involving 40 M/ME episodes of unknown aetiology, recruited from May 2021 to July 2022. All participants had previously tested negative with the FilmArray Meningitis/Encephalitis Panel. HCSS was used to detect viral nucleic acid in the patients' CSF. Sequencing was performed on Illumina NovaSeq platform. Raw sequence data were analysed using CZ ID metagenomics and PikaVirus bioinformatics pipelines. RESULTS: Forty episodes of M/ME of unknown aetiology in 39 children were analysed by HCSS. A significant viral detection in 30 CSF samples was obtained, including six parechovirus A, three enterovirus ACD, four polyomavirus 5, three HHV-7, two BKV, one HSV-1, one VZV, two CMV, one EBV, one influenza A virus, one rhinovirus, and 13 HERV-K113 detections. Of these, one sample with BKV, three with HHV-7, one with EBV, and all HERV-K113 were confirmed by specific PCR. The requirement for Intensive Care Unit admission was associated with HCSS detections. CONCLUSION: This study highlights HCSS as a powerful tool for the investigation of undiagnosed cases of M/ME. Data generated must be carefully analysed and reasonable precautions must be taken before establishing association of clinical features with unexpected or novel virus findings.
Subject(s)
Metagenomics , Viruses , Humans , Child, Preschool , Prospective Studies , Female , Male , Child , Viruses/genetics , Viruses/isolation & purification , Viruses/classification , Infant , Metagenomics/methods , Encephalitis/virology , Encephalitis/cerebrospinal fluid , Encephalitis/diagnosis , Cerebrospinal Fluid/virology , Meningitis, Viral/virology , Meningitis, Viral/cerebrospinal fluid , Meningitis, Viral/diagnosis , Adolescent , High-Throughput Nucleotide Sequencing , Spain , Meningitis/virology , Meningitis/cerebrospinal fluid , Meningitis/diagnosis , Encephalitis, Viral/virology , Encephalitis, Viral/cerebrospinal fluid , Encephalitis, Viral/diagnosisABSTRACT
BACKGROUND: Opportunistic infections in the central nervous system (CNS) can be a serious threat to people living with HIV. Early aetiological diagnosis and targeted treatment are crucial but difficult. Metagenomic next-generation sequencing (mNGS) has significant advantages over traditional detection methods. However, differences in the cerebrospinal fluid (CSF) microbiome profiles of patients living with and without HIV with suspected CNS infections using mNGS and conventional testing methods have not yet been adequately evaluated. METHODS: We conducted a retrospective cohort study in the first hospital of Changsha between January 2019 and June 2022 to investigate the microbiomes detected using mNGS of the CSF of patients living with and without HIV with suspected CNS infections. The pathogens causing CNS infections were concurrently identified using both mNGS and traditional detection methods. The spectrum of pathogens identified was compared between the two groups. RESULTS: Overall, 173 patients (140 with and 33 without HIV) with suspected CNS infection were enrolled in our study. In total, 106 (75.7%) patients with and 16 (48.5%) patients without HIV tested positive with mNGS (p = 0.002). Among the enrolled patients, 71 (50.7%) with HIV and five (15.2%) without HIV tested positive for two or more pathogens (p < 0.001). Patients with HIV had significantly higher proportions of fungus (20.7% vs. 3.0%, p = 0.016) and DNA virus (59.3% vs. 21.2%, p < 0.001) than those without HIV. Epstein-Barr virus (33.6%) was the most commonly identified potential pathogen in the CSF of patients living with HIV using mNGS, followed by cytomegalovirus (20.7%) and torque teno virus (13.8%). The top three causative pathogens identified in patients without HIV were Streptococcus (18.2%), Epstein-Barr virus (12.1%), and Mycobacterium tuberculosis (9.1%). In total, 113 patients living with HIV were diagnosed as having CNS infections. The rate of pathogen detection in people living with HIV with a CNS infection was significantly higher with mNGS than with conventional methods (93.8% vs. 15.0%, p < 0.001). CONCLUSION: CSF microbiome profiles differ between patients living with and without HIV with suspected CNS infection. mNGS is a powerful tool for the diagnosis of CNS infection among people living with HIV, especially in those with mixed infections.
Subject(s)
Central Nervous System Infections , Cerebrospinal Fluid , HIV Infections , High-Throughput Nucleotide Sequencing , Metagenomics , Humans , Male , Retrospective Studies , Female , High-Throughput Nucleotide Sequencing/methods , Adult , Middle Aged , Central Nervous System Infections/cerebrospinal fluid , Central Nervous System Infections/microbiology , Central Nervous System Infections/diagnosis , Central Nervous System Infections/virology , HIV Infections/complications , HIV Infections/cerebrospinal fluid , Metagenomics/methods , Cerebrospinal Fluid/microbiology , Cerebrospinal Fluid/virology , Microbiota/genetics , AIDS-Related Opportunistic Infections/cerebrospinal fluid , AIDS-Related Opportunistic Infections/microbiology , AIDS-Related Opportunistic Infections/diagnosisABSTRACT
Neurological symptoms highlight the need to understand pathophysiologic mechanisms.
Subject(s)
COVID-19/complications , Mental Disorders/etiology , Nervous System Diseases/etiology , Autoimmunity , Brain/immunology , Brain/pathology , COVID-19/immunology , COVID-19/physiopathology , COVID-19/virology , Cerebrospinal Fluid/immunology , Cerebrospinal Fluid/virology , Humans , Mental Disorders/immunology , Mental Disorders/physiopathology , Nervous System Diseases/immunology , Nervous System Diseases/physiopathology , Neuroinflammatory Diseases/etiology , Neuroinflammatory Diseases/immunology , Neuroinflammatory Diseases/physiopathology , SARS-CoV-2/isolation & purification , Post-Acute COVID-19 SyndromeABSTRACT
Cognitive post-acute sequelae of SARS-CoV-2 (PASC) can occur after mild COVID-19. Detailed clinical characterizations may inform pathogenesis. We evaluated 22 adults reporting cognitive PASC and 10 not reporting cognitive symptoms after mild SARS-CoV-2 infection through structured interviews, neuropsychological testing, and optional cerebrospinal fluid (CSF) evaluations (53%). Delayed onset of cognitive PASC occurred in 43% and associated with younger age. Cognitive PASC participants had a higher number of pre-existing cognitive risk factors (2.5 vs. 0; p = 0.03) and higher proportion with abnormal CSF findings (77% vs. 0%; p = 0.01) versus controls. Cognitive risk factors and immunologic mechanisms may contribute to cognitive PASC pathogenesis.
Subject(s)
COVID-19/physiopathology , Cerebrospinal Fluid/virology , Cognition/physiology , SARS-CoV-2/pathogenicity , Adult , Aged , COVID-19/cerebrospinal fluid , Disease Progression , Female , Humans , Male , Middle Aged , Research Personnel , Risk Factors , Young AdultABSTRACT
HISTORY: A 35-year-old, previously healthy woman presented with short history of headache and fever. Several other family members reported active hand, foot, and mouth disease. FINDINGS: Clinical findings showed subfebrile temperatures and a prominent meningism. Cerebrospinal fluid and computed tomography of the head were unrevealing. Subsequent PCR-analysis of the cerebrospinal fluid was positive for Enteroviral-RNA. DIAGNOSIS AND THERAPY: Enteroviral-meningitis was diagnosed. The empirically administered antimicrobial therapy was stopped and further diagnostic tests could be withheld. COURSE: Symptom-oriented therapy resulted in complete resolution within the next few days. CONCLUSIONS: Our case emphasizes that, in patients with typical signs of meningeal irritation, normal cellular analysis of the cerebrospinal fluid does not exclude the presence of infectious meningitis. The astute clinician should be reminded that this constellation is highly suggestive of enteroviral meningitis.
Subject(s)
Cerebrospinal Fluid/virology , Enterovirus Infections , Meningitis, Viral , Adult , Enterovirus Infections/cerebrospinal fluid , Enterovirus Infections/diagnosis , Female , Fever/virology , Headache/virology , Humans , Meningitis, Viral/cerebrospinal fluid , Meningitis, Viral/diagnosisABSTRACT
HIV-1 replication within the central nervous system (CNS) impairs neurocognitive function and has the potential to establish persistent, compartmentalized viral reservoirs. The origins of HIV-1 detected in the CNS compartment are unknown, including whether cells within the cerebrospinal fluid (CSF) produce virus. We measured viral RNA+ cells in CSF from acutely infected macaques longitudinally and people living with early stages of acute HIV-1. Active viral transcription (spliced viral RNA) was present in CSF CD4+ T cells as early as four weeks post-SHIV infection, and among all acute HIV-1 specimens (N = 6; Fiebig III/IV). Replication-inactive CD4+ T cell infection, indicated by unspliced viral RNA in the absence of spliced viral RNA, was even more prevalent, present in CSF of >50% macaques and human CSF at ~10-fold higher frequency than productive infection. Infection levels were similar between CSF and peripheral blood (and lymph nodes in macaques), indicating comparable T cell infection across these compartments. In addition, surface markers of activation were increased on CSF T cells and monocytes and correlated with CSF soluble markers of inflammation. These studies provide direct evidence of HIV-1 replication in CD4+ T cells and broad immune activation in peripheral blood and the CNS during acute infection, likely contributing to early neuroinflammation and reservoir seeding. Thus, early initiation of antiretroviral therapy may not be able to prevent establishment of CNS viral reservoirs and sources of long-term inflammation, important targets for HIV-1 cure and therapeutic strategies.
Subject(s)
CD4-Positive T-Lymphocytes/virology , Central Nervous System/virology , Cerebrospinal Fluid/virology , HIV Infections/virology , Simian Acquired Immunodeficiency Syndrome/virology , Animals , HIV-1 , Humans , Macaca mulatta , RNA, Viral/cerebrospinal fluid , Simian Immunodeficiency VirusABSTRACT
The SARS-CoV-2 and its variants are still hitting the world. Ever since the outbreak, neurological involvements as headache, ageusia, and anosmia in COVID-19 patients have been emphasized and reported. But the pathogenesis of these new-onset neurological manifestations in COVID-19 patients is still obscure and controversial. As difficulty always lay in the diagnosis of neurological infection, current reports to validate the presence of SARS-CoV-2 in cerebrospinal fluid (CSF) almost relied on the basic methods and warranted improvement. Here we reported a case series of 8 patients with prominent new-onset neurological manifestations, who were screened out from a patch of 304 COVID-19 confirmed patients. Next-generation sequencing (NGS) and proteomics were conducted in the simultaneously obtained CSF and serum samples of the selected patients, with three non-COVID-19 patients with matched demographic features used as the controls for proteomic analysis. SARS-CoV-2 RNA was detected in the CSF of four COVID-19 patients and was suspicious in the rest four remaining patients by NGS, but was negative in all serum samples. Proteomic analysis revealed that 185 and 59 proteins were differentially expressed in CSF and serum samples, respectively, and that only 20 proteins were shared, indicating that the proteomic changes in CSF were highly specific. Further proteomic annotation highlighted the involvement of complement system, PI3K-Akt signaling pathway, enhanced cellular interaction, and macrophages in the CSF proteomic alterations. This study, equipped with NGS and proteomics, reported a high detection rate of SARS-CoV-2 in the CSF of COVID-19 patients and the proteomic alteration of CSF, which would provide insights into understanding the pathological mechanism of SARS-CoV-2 CNS infection.
Subject(s)
COVID-19/cerebrospinal fluid , Central Nervous System Diseases/virology , Cerebrospinal Fluid/metabolism , Cerebrospinal Fluid/virology , RNA, Viral/cerebrospinal fluid , Adult , Aged , Aged, 80 and over , Female , High-Throughput Nucleotide Sequencing , Humans , Male , Middle Aged , Proteomics , SARS-CoV-2 , Sequence Analysis, RNAABSTRACT
Background High efficacy disease modifying therapies (DMT) in the management of Multiple Sclerosis (MS) have a favorable effect on relapse rate and disability progression; however, they can expose patients to significant risks, such as progressive multifocal leukoencephalopathy (PML). Objective The study aims to investigate prognostic factors that can determine outcome in MS-related PML patients. Methods We conducted a literature review and meta-analysis of 194 patients from 62 articles in PubMed, SCOPUS and EMBASE. Results Out of 194 patients (66.5% women, 33.5% men), 81% had progression in their EDSS score by at least 1 point from the time of PML diagnosis (EDSS-P group). The remaining patients had either stable or improved EDSS (EDSS-S group). In univariate analysis, older age at the time of PML diagnosis was associated with higher probability of disability accumulation and worsening of EDSS by at least 1 point (mean ageâ¯=â¯44.8, pâ¯=â¯0.046). After adjusting for other variables, age at time of PML diagnosis remained a significant predictive variable in the multivariable logistic model (ORâ¯=â¯0.93, 95% CI: 0.88-0.99, pâ¯=â¯0.037). Natalizumab is the most commonly associated DMT linked to PML, followed by fingolimod and others including dimethyl fumarate, ocrelizumab, alemtuzumab. Among the different treatments used, no therapeutic agent was found to be superior in improving post-PML EDSS. Conclusions Younger age and lower JCV viral load at the time of PML diagnosis were associated with better outcome in MS-associate PML, while none of the PML therapies was superior over the others or associated with favorable outcome.
Subject(s)
Antirheumatic Agents/adverse effects , Cerebrospinal Fluid/virology , JC Virus/isolation & purification , Leukoencephalopathy, Progressive Multifocal/etiology , Multiple Sclerosis/drug therapy , Age Factors , Antirheumatic Agents/therapeutic use , Disability Evaluation , Disease Progression , Endemic Diseases , Female , Humans , Immunocompromised Host , Leukoencephalopathy, Progressive Multifocal/cerebrospinal fluid , Leukoencephalopathy, Progressive Multifocal/virology , Male , Multiple Sclerosis/complications , Multiple Sclerosis/virology , Natalizumab/adverse effects , Natalizumab/therapeutic use , Prognosis , Severity of Illness Index , Viral LoadABSTRACT
The sandfly fever Toscana virus (TOSV, genus Phlebovirus, family Phenuiviridae) is endemic in Mediterranean countries. In Spain, phylogenetic studies of TOSV strains demonstrated that a genotype, different from the Italian, was circulating. This update reports 107 cases of TOSV neurological infection detected in Andalusia from 1988 to 2020, by viral culture, serology and/or RT-PCR. Most cases were located in Granada province, a hyperendemic region. TOSV neurological infection may be underdiagnosed since few laboratories include this virus in their portfolio. This work presents a reliable automated method, validated for the detection of the main viruses involved in acute meningitis and encephalitis, including the arboviruses TOSV and West Nile virus. This assay solves the need for multiple molecular platforms for different viruses and thus, improves the time to results for these syndromes, which require a rapid and efficient diagnostic approach.
Subject(s)
Bunyaviridae Infections/diagnosis , Cerebrospinal Fluid/virology , Encephalitis, Arbovirus/diagnosis , Meningitis, Viral/diagnosis , Sandfly fever Naples virus , Automation, Laboratory , Encephalitis, Arbovirus/virology , Humans , Meningitis, Viral/virology , Real-Time Polymerase Chain Reaction , Reverse Transcriptase Polymerase Chain Reaction , Sandfly fever Naples virus/immunology , Sandfly fever Naples virus/isolation & purification , Serologic TestsABSTRACT
Coronavirus disease 2019 (COVID-19) has been shown to be associated with a lot of neurological complications, of whom Guillain-Barre syndrome (GBS) is an important post-infectious consequentiality. More than 220 patients with GBS have been reported thus far. We intend to share our experience with five patients of GBS where one of them had severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the cerebrospinal fluid (CSF). This is the first-ever report demonstrating the presence of SARS-CoV-2 in the CSF of an adult patient; a similar occurrence has recently been described in a pediatric patient. We wish to emphasize the fact that commonly GBS occurs as a result of a post-infectious process but in a few cases where the symptoms of COVID-19 and GBS occur concurrently, corresponding to the viremic phase, separate pathogenesis needs to be thought of. This para-infectious nature is exemplified by the presence of virus in the cerebrospinal fluid of one of our patients. We review the neuroinvasive potential of SARS-Cov-2 in this regard and draw parallels with Cytomegalovirus, Zika virus, and Human Immunodeficiency virus-associated occurrences of GBS.
Subject(s)
COVID-19/complications , Guillain-Barre Syndrome/etiology , Adult , COVID-19/cerebrospinal fluid , COVID-19/therapy , Cerebrospinal Fluid/virology , Female , Guillain-Barre Syndrome/cerebrospinal fluid , Humans , Immunoglobulins, Intravenous/administration & dosage , Male , Middle Aged , SARS-CoV-2/isolation & purification , SARS-CoV-2/pathogenicity , Treatment OutcomeSubject(s)
COVID-19 , Cerebrospinal Fluid , Confusion , Encephalitis , Glucocorticoids/administration & dosage , Hashimoto Disease , SARS-CoV-2/isolation & purification , Brain/diagnostic imaging , COVID-19/diagnosis , COVID-19/physiopathology , COVID-19/psychology , Cerebrospinal Fluid/immunology , Cerebrospinal Fluid/virology , Confusion/diagnosis , Confusion/etiology , Dose-Response Relationship, Drug , Encephalitis/diagnosis , Encephalitis/etiology , Encephalitis/immunology , Encephalitis/therapy , Hashimoto Disease/diagnosis , Hashimoto Disease/etiology , Hashimoto Disease/immunology , Hashimoto Disease/therapy , Humans , Male , Middle Aged , Neurologic Examination/methods , Tomography, X-Ray Computed/methods , Treatment OutcomeSubject(s)
Anti-N-Methyl-D-Aspartate Receptor Encephalitis/diagnosis , Autoantibodies/blood , Cerebrospinal Fluid/virology , Encephalitis, Herpes Simplex/immunology , Simplexvirus/isolation & purification , Acyclovir/administration & dosage , Acyclovir/therapeutic use , Administration, Intravenous , Anti-N-Methyl-D-Aspartate Receptor Encephalitis/blood , Anti-N-Methyl-D-Aspartate Receptor Encephalitis/therapy , Encephalitis, Herpes Simplex/blood , Encephalitis, Herpes Simplex/drug therapy , Humans , Magnetic Resonance Imaging , Male , Methylprednisolone/administration & dosage , Methylprednisolone/therapeutic use , Middle Aged , Neoplasm Recurrence, Local , Plasmapheresis , Polymerase Chain Reaction , Treatment OutcomeABSTRACT
To provide instructive clues for clinical practice and further research of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, we analyzed the existing literature on viral neuroinvasion of SARS-CoV-2 in coronavirus disease 2019 (COVID-19) patients. To date, SARS-CoV-2 has been detected in the cerebrospinal fluid (CSF) or brain parenchyma in quite a few patients, which provide undeniable evidence for the neuroinvasive potential of this novel coronavirus. In contrast with the cerebrum and cerebellum, the detection rate of SARS-CoV-2 was higher in the olfactory system and the brainstem, both of which also showed severe microgliosis and lymphocytic infiltrations. As compared with the number of patients who underwent viral testing in the central nervous system (CNS), the number of patients showing positive results seems very small. However, it seems too early to conclude that the neuroinvasion of SARS-CoV-2 is rare in COVID-19 patients because the detection methods or sampling procedures in some studies may not be suitable or sufficient to reveal the CNS infection induced by neurotropic viruses. Moreover, the primary symptoms and/or causes of death were distinctly different among examined patients, which probably caused more conspicuous pathological changes than those due to the direct infection that usually localized to specific brain areas. Unfortunately, most autopsy studies did not provide sufficient details about neurological symptoms or suspected diagnoses of the examined patients, and the documentation of neuropathological changes was often incomplete. Given the complex pathophysiology of COVID-19 and the characteristics of neurotropic viruses, it is understandable that any study of the CNS infection may inevitably have limitations.
Subject(s)
Brain/pathology , COVID-19/pathology , Cerebrospinal Fluid/virology , Olfactory Bulb/virology , Antibodies, Viral/blood , Antibodies, Viral/cerebrospinal fluid , Brain/virology , Humans , Nervous System Diseases/virology , Olfactory Mucosa/virology , SARS-CoV-2/isolation & purificationABSTRACT
This study was designed to evaluate whether severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) can directly target the central nervous system (CNS). We present four patients suffering from the loss of consciousness and seizure during the clinical course of COVID-19 infection. In addition to positive nasopharyngeal swab tests, SARS-CoV-2 has been detected in their cerebrospinal fluid. This report indicates the neuroinvasive potential of SARS-CoV-2, suggesting the ability of this virus to spread from the respiratory tract to the CNS.
Subject(s)
COVID-19/complications , Cerebrospinal Fluid/virology , SARS-CoV-2/isolation & purification , Seizures/virology , Severe Acute Respiratory Syndrome/virology , Aged , Female , Humans , Male , Middle Aged , Young AdultABSTRACT
The peculiar features of coronavirus disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), are challenging the current biological knowledge. Early in Feb, 2020, we suggested that SARS-CoV-2 may possess neuroinvasive potential similar to that of many other coronaviruses. Since then, a variety of neurological manifestations have been associated with SARS-CoV-2 infection, which was supported in some patients with neuroimaging and/or cerebrospinal fluid tests. To date, at least 27 autopsy studies on the brains of COVID-19 patients can be retrieved through PubMed/MEDLINE, among which neuropathological alterations were observed in the brainstem in 78 of 134 examined patients, and SARS-CoV-2 nucleic acid and viral proteins were detected in the brainstem in 16/49 (32.7%) and 18/71 (25.3%) cases, respectively. To shed some light on the peculiar respiratory manifestations of COVID-19 patients, this review assessed the existing evidence about the neurogenic mechanism underlying the respiratory failure induced by SARS-CoV-2 infection. Acknowledging the neurological involvement has important guiding significance for the prevention, treatment, and prognosis of SARS-CoV-2 infection.